Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 VALUE CHAIN ANALYSIS
15 HEALTHCARE ECONOMY
15.1 HEALTHCARE EXPENDITURE
15.2 CAPITAL EXPENDITURE
15.3 CAPEX TRENDS
15.4 CAPEX ALLOCATION
15.5 FUNDING SOURCES
15.6 INDUSTRY BENCHMARKS
15.7 GDP RATION IN OVERALL GDP
15.8 HEALTHCARE SYSTEM STRUCTURE
15.9 GOVERNMENT POLICIES
15.1 ECONOMIC DEVELOPMENT
16 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TECHNOLOGY
16.1 OVERVIEW
16.2 NEXT GENERATION SEQUENCING
16.3 WHOLE GENOME SEQUENCING
16.4 WHOLE EXOME SEQUENCING
16.5 TARGETED SEQUENCING & RESEQUENCING
16.6 OMICS
17 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY PRODUCT AND SERVICES
17.1 OVERVIEW
17.2 INSTRUMENTS
17.2.1 BY PRODUCT
17.2.1.1. WORKSTATION/PLATFORM
17.2.1.2. NEXT GENERATION SEQUENCERS
17.2.1.2.1. AUTMATED
17.2.1.2.2. SEMIAUTOMATED
17.2.1.3. OTHERS
17.2.2 BY TYPE
17.2.2.1. HIGH SEQUENCING
17.2.2.2. LOW SEQUENCING
17.2.3 BY MODALITY
17.2.3.1. STANDALONE
17.2.3.2. PORTABLES
17.2.3.3. BENCHTOP
17.3 CONSUMABLES
17.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING AND SIZE SELECTION
17.3.1.1. REAGENTS AND KITS
17.3.1.1.1. FAST HYBRIDIZATION AND WASH KIT
17.3.1.1.2. STANDARD HYBRIDIZATION AND WASH KIT
17.3.1.1.3. UNIVERSAL BLOCKER
17.3.1.1.4. METHYLATION DETECTION SYSTEM
17.3.1.1.5. OTHERS
17.3.1.2. OTHERS
17.3.2 LIBRARY PREPARATION
17.3.2.1. WHOLE GENOME KITS
17.3.2.1.1. 12 SAMPLE
17.3.2.1.1.1 WITH PREPARATION BEADS
17.3.2.1.1.2 WITHOUT PREPARATION BEADS
17.3.2.1.2. 24 SAMPLE
17.3.2.1.2.1 WITH PREPARATION BEADS
17.3.2.1.2.2 WITHOUT PREPARATION BEADS
17.3.2.1.3. 96 SAMPLE
17.3.2.1.3.1 WITH PREPARATION BEADS
17.3.2.1.3.2 WITHOUT PREPARATION BEADS
17.3.2.2. OTHERS
17.3.3 EXOME GENOMIC KITS
17.3.3.1. 12 SAMPLE
17.3.3.1.1. WITH PREPARATION BEADS
17.3.3.1.2. WITHOUT PREPARATION BEADS
17.3.3.2. 24 SAMPLE
17.3.3.2.1. WITH PREPARATION BEADS
17.3.3.2.2. WITHOUT PREPARATION BEADS
17.3.3.3. 96 SAMPLE
17.3.3.3.1. WITH PREPARATION BEADS
17.3.3.3.2. WITHOUT PREPARATION BEADS
17.3.3.3.3. OTHERS
17.3.4 TARGET ENRICHMENT
17.3.4.1. BY TARGETED REGION
17.3.4.1.1. 60 MB
17.3.4.1.2. 51 MB
17.3.4.1.3. 39 MB
17.3.4.1.4. OTHERS
17.3.4.2. BY PROBE TYPE
17.3.4.2.1. BIOTINYLATED CRNA BAITS
17.3.4.2.2. BIOTINYLATED DNA BAIT
17.3.4.2.3. OTHERS
17.3.4.3. OTHERS
17.4 SERVICES
17.4.1 SEQUENCING SERVICES
17.4.1.1. RNA SEQUENCING
17.4.1.2. WHOLE EXOME SEQUENCING
17.4.1.3. WHOLE GENOME SEQUENCING
17.4.1.4. TARGETED SEQUENCING
17.4.1.5. CHIP SEQUENCING
17.4.1.6. DE NOVO SEQUENCING
17.4.1.7. METHYL SEQUENCING
17.4.1.8. OTHERS
17.4.2 DATA MANAGEMENT SERVICES
17.4.2.1. NGS DATA ANALYSIS SERVICES
17.4.2.2. NGS DATA ANALYSIS SOFTWARE & WORKBENCHES
17.4.2.2.1. LIBRARIES FOR GENOMICS SCREENING
17.4.2.2.2. CRISPR-CAS9 SCREENING LIBRARIES
17.4.2.2.2.1 POOLED SGRNA
17.4.2.2.2.2 ARRAYED CRRNA
17.4.2.2.3. CRISPR ACTIVATION CRRNA LIBRARIES
17.4.2.2.3.1 GENE FAMILIES
17.4.2.2.3.2 DRUGGABLE
17.4.2.2.3.3 WHOLE HUMAN GENOME
17.4.2.2.4. RNAI SCREENING LIBRARIES
17.4.2.2.4.1 SIRNA
17.4.2.2.4.2 SHRNA
17.4.2.2.4.3 MICRORNA
17.4.2.2.5. CDNA AND ORF LIBRARIES
17.4.2.2.5.1 CCSB HUMAN ORFEOME
17.4.2.2.5.2 ORFEOME COLLABORATION
17.4.2.2.5.3 MAMMALIAN GENE COLLECTION
17.4.2.2.6. OTHERS
17.4.2.3. OMICS SERVICES
17.4.2.4. OTHERS
18 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY SEQUENCING TYPE
18.1 OVERVIEW
18.2 SINGLE-READ SEQUENCING
18.3 PAIRED-END SEQUENCING
19 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY METHODS OF SEQUENCING
19.1 OVERVIEW
19.2 LOW THROUGHPUT
19.3 MEDIUM THROUGHPUT
19.4 HIGH THROUGHPUT
20 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY APPLICATION
20.1 OVERVIEW
20.2 PRECISION MEDICINE FOR CANCER
20.3 LIQUID BIOPSY
20.4 MINIMAL RESIDUAL DISEASE (MRD) MONITORING
20.5 CANCER IMMUNOTHERAPY
20.6 OTHERS
21 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY CANCER TYPE
21.1 OVERVIEW
21.2 BREAST CANCER
21.3 LUNG CANCER
21.4 COLORECTAL CANCER
21.5 PROSTATE CANCER
21.6 LEUKEMIA
21.7 LYMPHOMA
21.8 MELANOMA
21.9 OTHERS
22 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY END USER
22.1 OVERVIEW
22.2 HOSPITALS
22.2.1 PUBLIC
22.2.2 PRIVATE
22.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
22.3.1 SMALL
22.3.2 MEDIUM
22.3.3 LARGE
22.4 ACADEMIC & RESEARCH INSTITUTES
22.5 CLINICAL LABORATORIES
22.6 GOVERNMENT INSTITUTES
22.7 FORENSIC LABORATORIES
22.8 CONTRACT RESEARCH ORGANIZATIONS (CROS)
22.9 OTHERS
23 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY DISTRUBUTION CHANNEL
23.1 OVERVIEW
23.2 DIRECT TENDERS
23.3 RETAIL SALES
23.4 OTHERS
24 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY REGION
24.1 GLOBAL MEDICAL CARTS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.2 NORTH AMERICA
24.2.1 U.S.
24.2.2 CANADA
24.2.3 MEXICO
24.3 EUROPE
24.3.1 GERMANY
24.3.2 FRANCE
24.3.3 U.K.
24.3.4 ITALY
24.3.5 SPAIN
24.3.6 RUSSIA
24.3.7 TURKEY
24.3.8 BELGIUM
24.3.9 NETHERLANDS
24.3.10 SWITZERLAND
24.3.11 REST OF EUROPE
24.4 ASIA-PACIFIC
24.4.1 JAPAN
24.4.2 CHINA
24.4.3 SOUTH KOREA
24.4.4 INDIA
24.4.5 AUSTRALIA
24.4.6 SINGAPORE
24.4.7 THAILAND
24.4.8 MALAYSIA
24.4.9 INDONESIA
24.4.10 PHILIPPINES
24.4.11 REST OF ASIA-PACIFIC
24.5 SOUTH AMERICA
24.5.1 BRAZIL
24.5.2 ARGENTINA
24.5.3 REST OF SOUTH AMERICA
24.6 MIDDLE EAST AND AFRICA
24.6.1 SOUTH AFRICA
24.6.2 SAUDI ARABIA
24.6.3 UAE
24.6.4 EGYPT
24.6.5 ISRAEL
24.6.6 REST OF MIDDLE EAST AND AFRICA
24.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: GLOBAL
25.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
25.3 COMPANY SHARE ANALYSIS: EUROPE
25.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
25.5 MERGERS & ACQUISITIONS
25.6 NEW PRODUCT DEVELOPMENT & APPROVALS
25.7 EXPANSIONS & PARTNERSHIP
25.8 REGULATORY CHANGES
26 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, SWOT AND DBMR ANALYSIS
27 GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, COMPANY PROFILE
27.1 ACT GENOMICS
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
27.2 RESOLUTION BIOSCIENCE, INC. (AGILENT TECHNOLOGIES, INC.)
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPMENTS
27.3 ILLUMINA, INC.
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPMENTS
27.4 BD
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPMENTS
27.5 BERRY GENOMICS
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPMENTS
27.6 BIO-RAD LABORATORIES, INC.
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPMENTS
27.7 DNASTAR
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPMENTS
27.8 EUROFINS GENOMICS
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPMENTS
27.9 QIAGEN
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPMENTS
27.1 CARIS LIFE SCIENCES
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPMENTS
27.11 F. HOFFMANN-LA ROCHE LTD
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPMENTS
27.12 THERMO FISHER SCIENTIFIC INC
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPMENTS
27.13 MYRIAD GENETICS, INC
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPMENTS
27.14 BGI
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPMENTS
27.15 REVVITY
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPMENTS
27.16 FOUNDATION MEDICINE, INC.,
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPMENTS
27.17 PACBIO
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPMENTS
27.18 OXFORD NANOPORE TECHNOLOGIES PLC.
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPMENTS
27.19 GRAPHPAD SOFTWARE, LLC,
27.19.1 COMPANY OVERVIEW
27.19.2 REVENUE ANALYSIS
27.19.3 GEOGRAPHIC PRESENCE
27.19.4 PRODUCT PORTFOLIO
27.19.5 RECENT DEVELOPMENTS
27.2 MACROGEN, INC.
27.20.1 COMPANY OVERVIEW
27.20.2 REVENUE ANALYSIS
27.20.3 GEOGRAPHIC PRESENCE
27.20.4 PRODUCT PORTFOLIO
27.20.5 RECENT DEVELOPMENTS
27.21 AZENTA LIFE SCIENCES
27.21.1 COMPANY OVERVIEW
27.21.2 REVENUE ANALYSIS
27.21.3 GEOGRAPHIC PRESENCE
27.21.4 PRODUCT PORTFOLIO
27.21.5 RECENT DEVELOPMENTS
27.22 TAKARA BIO INC.
27.22.1 COMPANY OVERVIEW
27.22.2 REVENUE ANALYSIS
27.22.3 GEOGRAPHIC PRESENCE
27.22.4 PRODUCT PORTFOLIO
27.22.5 RECENT DEVELOPMENTS
27.23 NOVOGENE CO, LTD.
27.23.1 COMPANY OVERVIEW
27.23.2 REVENUE ANALYSIS
27.23.3 GEOGRAPHIC PRESENCE
27.23.4 PRODUCT PORTFOLIO
27.23.5 RECENT DEVELOPMENTS
27.24 STANDARD BIOTOOLS INC.
27.24.1 COMPANY OVERVIEW
27.24.2 REVENUE ANALYSIS
27.24.3 GEOGRAPHIC PRESENCE
27.24.4 PRODUCT PORTFOLIO
27.24.5 RECENT DEVELOPMENTS
27.25 CREATIVE BIOLABS
27.25.1 COMPANY OVERVIEW
27.25.2 REVENUE ANALYSIS
27.25.3 GEOGRAPHIC PRESENCE
27.25.4 PRODUCT PORTFOLIO
27.25.5 RECENT DEVELOPMENTS
27.26 ZYMO RESEARCH CORPORATION
27.26.1 COMPANY OVERVIEW
27.26.2 REVENUE ANALYSIS
27.26.3 GEOGRAPHIC PRESENCE
27.26.4 PRODUCT PORTFOLIO
27.26.5 RECENT DEVELOPMENTS
27.27 VERACYTE, INC
27.27.1 COMPANY OVERVIEW
27.27.2 REVENUE ANALYSIS
27.27.3 GEOGRAPHIC PRESENCE
27.27.4 PRODUCT PORTFOLIO
27.27.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
28 RELATED REPORTS
29 CONCLUSION
30 QUESTIONNAIRE
31 ABOUT DATA BRIDGE MARKET RESEARCH
